Hit triage using efficiency indices after screening of compound libraries in drug discovery

Current Topics in Medicinal Chemistry

Volumn 9, Issue 18, 2009, Pages 1718-1724

  Reitz, Allen B ^a   Smith, Garry R ^a   Tounge, Brett A ^b   Reynolds, Charles H ^b  

^a Fox Chase Chemical Diversity Center Inc   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE INHIBITOR; GEFITINIB; HALOPERIDOL; MOLECULAR LIBRARY;

BINDING AFFINITY; BIOPHYSICS; CALCULATION; DATA ANALYSIS; DRUG EFFICACY; DRUG SCREENING; FIT QUANTITY; FRAGMENT BASED DRUG DISCOVERY; LIGAND BINDING; LIGAND EFFICIENCY; MOLECULAR SIZE; MOLECULAR WEIGHT; PARAMETER; REVIEW; STANDARDIZATION; CHEMISTRY; DRUG DESIGN; DRUG DEVELOPMENT; HUMAN; MOLECULAR LIBRARY; PHARMACOLOGY; PROCEDURES; STRUCTURE ACTIVITY RELATION; THEORETICAL MODEL;

DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, THEORETICAL; MOLECULAR WEIGHT; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 74249090351     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609790102365     Document Type: Review

References (34)

1. Pharma Insight summary report from Wolters Kluwer Health: http://www.wolterskluwer.com/WK/Press/Latest+News/2009/Apr/pr07apr09a.htm 2009
2. Fink, T.; Reymond, J.-L. Virtual exploration of the chemical universe up to 11 atoms of C, N, O. F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. J. Chem. Inf. Model. 2007, 47, 342-353.
3. rd ed., Academic Press: Amsterdam, 2008, pp. 228-243.
4. Hadjuk, P. J.; Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 2007, 6, 211-219.
5. Bartoli, S.; Fincham, C. I.; Fattori, D. The fragment-approach: an update. Drug Discov. Today: Technol. 2006, 3, 425-431.
6. Rees, D. C.; Cosgreve, M.; Murray, C. W.; Carr, R. Fragment-based lead discovery. Nat. Rev. Drug. Discov. 2004, 3, 660-672.
7. Erlanson, D. A.; McDowell, R. S.; O'Brien, T. Fragment-based drug discovery. J. Med. Chem. 2007, 47, 3463-3482.
8. Jahnke, W.; Erlanson, D. A. Fragment-Based Approaches in Drug Discovery. Wiley-VCH Verlag GmbH & Co. KgaA: Weinheim, 2006, pp. 1-369.
9. Verdonk, M. L.; Hartshorn, M. J. Structure-guided fragment screening for lead discovery. Curr. Opin. Drug Discov. Dev. 2004, 7, 404, 404-410.
10. Davis, A. M.; Keeling, D. J.; Steele, J.; Tomkinson, N. P.; Tinker, A. C. Components of successful lead generation. Curr. Top. Med. Chem. 2005, 5, 421-439.
11. Hann, M. M.; Leach, A. R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
12. Schuffenhauer, A.; Ruedisser, S.; Marzinzik, A.; Jahnke, W.; Selzer, P.; Jacoby, E. Library design for fragment based screening. Curr. Top. Med. Chem., 2005, 5, 751-762.
13. Lipinski, C. A.; Hopkins, A. Navigating chemical space for biology and medicine. Nature 2004, 432, 855-861.
14. Siegel, M. G.; Vieth, M. Drugs in Other Drugs: A New Look at Drugs as Fragments. Drug Discov. Today 2006, 12, 71-79.
15. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A "Rule of Three" for fragment based lead discovery? Drug Discov. Today 2003, 8, 876-877.
16. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 2000, 43, 3714-3717.
17. Wood, W. J. L.; Patterson, A. W.; Tsuruoka, H.; Jain, R. K.; Ellman, J. A. Substrate activity screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors. J. Am. Chem. Soc. 2005, 127, 15521-15527.
18. Manetsch, R.; Krasinski, A.; Radic, Z.; Raushel, J.; Taylor, P.; Sharpless, K. B.; Kolb, H. C. In situ click chemistry: enzyme inhibitors made to their own specifications. J. Am. Chem. Soc. 2004, 126, 12809-12818.
19. Jencks, W. P. On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. USA 1981, 78, 4046-4050.
20. Nakamura, C. E.; Abeles, R. H. Mode of interaction of β-hydroxy-β-methylglutaryl coenzyme a reductase with strong binding inhibitors: compactin and related compounds. Biochemistry 1985, 24, 1364-1376.
21. Mutschler E.; Derendorf, H. Drug Action: Basic Principles and Therapeutic Aspects; Schäfer-Kortling, Stuttgart, 1995.
22. Abad-Zapatero, C.; Metz, J. T. Ligand efficiency indices as guideposts for drug discovery. Drug Discov. Today 2005, 10, 464-469.
23. Hetényi, C.; Maran, U.; García-Sosa, A. T.; Karelson, M. Structure based calculation of drug efficiency indices. Bioinformatics 2007, 23, 2678-2685.
24. Bembenek, S. D.; Tounge, B. A.; Reynolds, C. H. Ligand efficiency and fragment-based drug discovery. Drug Discov. Today 2009, 14, 278-283.
25. Reynolds, C.; Bembenek, S.; Tounge, B. The role of molecular size in ligand efficiency. Bioorg. Med. Chem. Lett. 2007, 17, 4258-4261.
26. Reynolds, C.; Tounge, B.; Bembenek, S. Ligand binding efficiency: Trends, physical basis, and implications. J. Med. Chem. 2008, 51, 2432-2438.
27. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 2004, 9, 430-431.
28. Andrews, P. R.; Craik, D. J.; Martin, J. L. Functional group contributions to drug-receptor interactions. J. Med. Chem. 1984, 27, 1648-1657.
29. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands. Proct. Natl. Acad. Sci. USA 1999, 96, 9997-10002.
30. Babaoglu, K.; Shoichet, B. K. Deconstructing fragment-based inhibitor discovery. Nat. Chem. Biol. 2006, 2, 720-723.
31. Hadjuk, P. Fragment-based drug design: how big is too big. J. Med. Chem. 2006, 49, 6972-6976.
32. Liebeschuetz, J. W.; Jones, S. D.; Morgan, P. J.; Murray, C. W.; Rimmer, A. D.; Roscoe, J. M. E.; Waszkowycz, B.; Welsh, P. M.; Wylie, W. A.; Young, S. C.; Martin, H.; Mahler, J.; Brady, L.; Wilkinson, K. PROSELECT: Combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors. J. Med. Chem. 2002, 45, 1221-1232.
33. Saxty, G.; Woodhead, S. J.; Berdini, V.; Davies, T. G.; Verdonk, M. L.; Wyatt, P. G.; Boyle, R. G.; Barford, D.; Downham, R.; Garrett, M. D.; Carr, R. A. Identification of inhibitors of protein kinase B using fragment-based lead discovery. J. Med. Chem. 2007, 50, 2293-2296.
34. Palm, K.; Stenberg, P.; Luthman, K.; Artursson, P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 1997, 14, 568-571.